<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05040503</url>
  </required_header>
  <id_info>
    <org_study_id>QUENOT 2020-2</org_study_id>
    <nct_id>NCT05040503</nct_id>
  </id_info>
  <brief_title>Monitoring Mitophagy In Myeloid Cells Upon Intensive Care</brief_title>
  <acronym>MIMIC</acronym>
  <official_title>Monitoring Mitophagy In Myeloid Cells Upon Intensive Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Severe infections (sepsis) are a frequent cause of admission to the intensive care unit.&#xD;
      Sepsis represent a significant risk for the health of patients in the short and medium term.&#xD;
      Sepsis are notably linked to a change in the function of immune cells. In some patients, a&#xD;
      state of pseudo-dormancy of monocyte and macrophage immune cells, called myeloid cell&#xD;
      immunosuppression, is observed. This situation, which leads to a worsening of the infection,&#xD;
      must be avoided because it represents a danger for the patient, even during antibiotic&#xD;
      therapy. At present, these events are still very poorly understood. Research is needed to&#xD;
      understand how the immunosuppression of myeloid cells occurs in order to adapt existing&#xD;
      treatments or to find new ones.&#xD;
&#xD;
      Laboratory work on animal models of sepsis has shown that this state of myeloid cell&#xD;
      immunosuppression is closely linked to a modification of energy production by myeloid cells&#xD;
      (monocytes and macrophages). The function of the mitochondria (&quot;energy factory&quot; of the cells)&#xD;
      in these cells is impaired. Thus, restoring mitochondrial function in myeloid cells could be&#xD;
      a therapeutic solution against the immunosuppression of myeloid cells during severe sepsis.&#xD;
&#xD;
      The aim of this study is to verify whether alterations in mitochondrial function in myeloid&#xD;
      cells occur in both patients with and without bacterial infection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 25, 2021</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Level of mitophagy</measure>
    <time_frame>at admission and at 24 hours post-admission</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Septicemia</condition>
  <arm_group>
    <arm_group_label>Patients without sepsis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patient without sepsis admitted to the Intensive Care Unit or the Anesthesia and Intensive Care Unit of the Dijon University Hospital</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with sepsis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with sepsis admitted to the Intensive Care Unit or the Anesthesia and Intensive Care Unit of the Dijon University Hospital</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with septic shock</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with septic shock admitted to the Intensive Care Unit or the Anesthesia and Intensive Care Unit of the Dijon University Hospital</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sampling at inclusion</intervention_name>
    <description>Sampling of 2 tubes of 3 ml:&#xD;
patient: H0: 0-6h post-admission&#xD;
healthy volunteer: at inclusion</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Patients with sepsis</arm_group_label>
    <arm_group_label>Patients with septic shock</arm_group_label>
    <arm_group_label>Patients without sepsis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sampling at 24 hours</intervention_name>
    <description>Collection of 2 tubes of 3 ml (H24: 24-30h post-admission)</description>
    <arm_group_label>Patients with sepsis</arm_group_label>
    <arm_group_label>Patients with septic shock</arm_group_label>
    <arm_group_label>Patients without sepsis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Data collection</intervention_name>
    <description>clinical and biological medical data for patients and general health data for healthy volunteers</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Patients with sepsis</arm_group_label>
    <arm_group_label>Patients with septic shock</arm_group_label>
    <arm_group_label>Patients without sepsis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Criteria common to all 4 groups:&#xD;
&#xD;
          -  Patient (and/or trusted person/health care proxy or relative) or volunteer who&#xD;
             provided oral consent after receiving information about the study, or patient included&#xD;
             in emergency situation&#xD;
&#xD;
          -  Age â‰¥ 18 years&#xD;
&#xD;
        Common criteria for patients&#xD;
&#xD;
        - Admission to the Intensive Care Unit or the Anesthesia and Intensive Care Unit of the&#xD;
        Dijon University Hospital&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Person not affiliated to national health insurance&#xD;
&#xD;
          -  Person subject to a measure of legal protection (curatorship, guardianship)&#xD;
&#xD;
          -  Person subject to limited judicial protection&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Known primary or secondary immune deficiency (radiotherapy, chemotherapy,&#xD;
             immunosuppressive treatment or systemic corticosteroid therapy in the 3 months&#xD;
             preceding inclusion (&gt; 0.15 mg/kg/d of prednisone equivalent for more than 2 weeks or&#xD;
             &quot;bolus&quot; greater than 2mg/kg/d of prednisone equivalent), HIV infection, primary&#xD;
             cellular immune deficiency)&#xD;
&#xD;
          -  Patients hospitalized within 3 months prior to inclusion for sepsis.&#xD;
&#xD;
          -  Patients receiving therapy known to modulate mitochondrial function, mitochondrial&#xD;
             biogenesis or mitophagy (chloroquine, hydroxychloroquine, rapamycin, carbamazepine,&#xD;
             resveratrol, sildenafil)&#xD;
&#xD;
          -  Patients with COVID-19&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean-Pierre QUENOT</last_name>
    <phone>03 80 29 36 85</phone>
    <email>jean-pierre.quenot@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre QUENOT</last_name>
      <phone>03 80 29 36 85</phone>
      <email>jean-pierre.quenot@chu-dijon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 30, 2021</study_first_submitted>
  <study_first_submitted_qc>September 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2021</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

